Compare YieldMax MSTR Option Income Strategy ETF (MSTY) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax MSTR Option Income Strategy ETF vs Revvity Inc — how do they compare? YieldMax MSTR Option Income Strategy ETF trades at $12.56, while Revvity Inc trades at $115.76 (market cap $12.94B). The key difference: Revvity Inc pays a 0.24% dividend while YieldMax MSTR Option Income Strategy ETF pays none, and Revvity Inc is trading nearer its 52-week high, YieldMax MSTR Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| MSTY | RVTY | |
|---|---|---|
Sector | Income / Options Overlay | Technology |
52-Week High | $95.95 | $117.75 |
52-Week Low | $11.55 | $82.26 |
Market Cap | — | $12.94B |
Enterprise Value | — | $15.26B |
Dividend Yield | — | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTY (YieldMax MSTR Option Income Strategy ETF) trades at $12.82, up 2.31% today, but remains in a significant downtrend with a 67% decline year-to-date. The ETF faces structural challenges as high distribution yields mask substantial NAV erosion, with technical indicators showing neutral momentum amid bearish moving averages. Recent news highlights concerns about the fund returning investor capital as distributions while experiencing deep losses.
The outlook remains challenged by the ETF's structural limitations that cap upside potential while exposing investors to full downside risk. Investment opportunity exists only for sophisticated investors seeking high current income despite principal erosion, while risks include continued NAV decline, tax inefficiency, and dependence on MicroStrategy's volatile performance.
RVTY trades at $114.66, up 0.37% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust fundamentals with a 54.98% gross margin and $241.20M net income for 2025, supported by positive news including product launches and raised 2026 guidance. Analyst consensus is a buy with a $120.50 price target, indicating potential upside from current levels.
Outlook remains positive due to consistent earnings outperformance and innovation in diagnostics, but risks include high P/E valuation and competitive pressures. Investors may find opportunity in sustained margin strength and AI integration, though macroeconomic sensitivity warrants caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About YieldMax MSTR Option Income Strategy ETF
MSTY is an actively managed ETF that pursues a synthetic covered call strategy on MicroStrategy Incorporated (MSTR) stock. The fund primarily sells call options on MSTR and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the volatile, Bitcoin-correlated growth potential of MSTR while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on MSTY →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
